Verismo Therapeutics to Use Cryoport’s IntegriCell® Cryopreservation Services in its Clinical KIR-CAR T Cell Therapy Programs
Verismo is ramping up its 2 Phase 1s targeting solid tumors and B-Cell non-Hodgkin lymphomas, selecting Cryoport for its cold chain.
Key Points
- Cryoport says Verismo Therapeutics has selected its IntegriCell cryopreservation services to support the clinical development of SynKIR-110 and SynKIR-310.
- The work includes process development, technology transfer, and clinical cryopreservation tied to Verismo’s multi-chain KIR-CAR T cell therapy programs.
- Both Verismo candidates are already in Phase 1 trials, targeting solid tumors and B-cell non-Hodgkin lymphomas.
Cryoport has been selected by Verismo Therapeutics to provide its IntegriCell cryopreservation services for Verismo’s lead KIR-CAR T cell therapy programs, SynKIR-110 and SynKIR-310. The partnership covers process development, technology transfer, and clinical cryopreservation support for the two candidates as they move from clinical development to commercialization.
IntegriCell will provide standardized, manufacture-ready cryopreserved leukapheresis starting material within a GMP-compliant quality system, with the goal of reducing variability and improving manufacturing efficiency. You can download their whitepaper here.
“Advancing a cell therapy program requires a partner that can help developers refine and scale critical processes as their programs mature,” said Dr. Mark Sawicki, CEO, Cryoport Systems. “By implementing Verismo’s existing proprietary cryopreservation process within our global quality management system, we enabled them to preserve their existing regulatory work while gaining the consistency and reliability of our bioprocessing, cryopreservation and distribution infrastructure.”
Verismo, a subsidiary of HLB Innovation, is developing a multi-chain KIR-CAR platform for solid tumors and B-cell associated disorders and malignancies. The company says its platform uses a modified NK cell-derived receptor and DAP12 pairing designed to improve T cell persistence and reduce exhaustion.
Its two lead programs are already in human trials. SynKIR-110 is being evaluated in the STAR-101 Phase 1 for patients with advanced mesothelin-expressing solid tumors. SynKIR-310 is being evaluated in the CELESTIAL-301 Phase 1 trial for patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Image credit – Cryoport.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
